Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24001938 | 1.00 | CHEK1 (0.49) | CHEK1CCNA2CDK2CCNA1DRD2 | |
| SCHEMBL24001714 | 1.00 | CHEK1 (0.49) | CHEK1CCNA2CDK2CCNA1DRD2 | |
| SCHEMBL31330686 | 0.98 | CHEK1 (0.48) | CHEK1CCNA2CDK2CCNA1DRD2 | |
| Hydrochloric Acid SCHEMBL26989017 | 0.98 | CHEK1 (0.48) | CHEK1CCNA2CDK2CCNA1DRD2 | |
| SCHEMBL27074359 | 0.84 | DRD2 (0.42) | DRD2DRD3 | |
| SCHEMBL25170240 | 0.84 | DRD2 (0.42) | DRD2DRD3 | |
| SCHEMBL27166633 | 0.82 | — | — | |
| SCHEMBL24009697 | 0.80 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL24836005 | 0.80 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL30792980 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747249-A1 | TREM2 MODULATORS | Muna Therapeutics ApS (DK) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026087634-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4727934-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720061-A1 | TREM2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720062-A1 | PYRIDO[3,4-D]PYRIMIDIN-4-ONE AND PYRIMIDO[5,4-D]PYRIMIDIN-4-ONE DERIVATIVES AS TREM2 AGONISTS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12459953-B2 | TREM2 modulators | MUNA THERAPEUTICS APS (DK) | 2025-11-04 | — | — | US | disclosed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250223294-A1 | TREM2 MODULATORS | MUNA THERAPEUTICS APS (DK) | 2025-07-10 | — | — | US | disclosed |
| WO-2022236272-A2 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2019-01-01 | — | — | US | disclosed |
| CN-108137600-A | Condensed pyrazole derivatives as kinase inhibitor | UCB生物制药私人有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-3102573-B1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | CHEK1 2951/4885CCNA2 2583/4885CDK2 1449/4885 |
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | P2RX7, P2RX1, P2RX2 | CHEK1 3700/4885CCNA2 4099/4885CDK2 1860/4885 |
| US-12459953-B2 | TREM2 modulators | FCER2, MERTK, FCGR1A | CHEK1 3429/4885CCNA2 4223/4885CDK2 2585/4885 |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | CHEK1 3700/4885CCNA2 4099/4885CDK2 1860/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | CHEK1 145/4885CCNA2 584/4885CDK2 154/4885 |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | CHEK1 3705/4885CCNA2 4124/4885CDK2 1866/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | CHEK1 145/4885CCNA2 584/4885CDK2 154/4885 |
| US-20250223294-A1 | TREM2 MODULATORS | FCER2, MERTK, FCGR1A | CHEK1 3429/4885CCNA2 4223/4885CDK2 2585/4885 |
| US-20250388574-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FCER2, HAVCR2 | CHEK1 3105/4885CCNA2 4166/4885CDK2 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.